ARQT vs VKTX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ARQT · Arcutis Biotherapeutics$25.55 ▼ 5.37%
VKTX · Viking Therapeutics$26.84 ▲ 4.07%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ARQT +7.6%
- VKTX -28.9%
Head to head
| Metric | ARQT | VKTX |
|---|---|---|
| Price | $25.55 | $26.84 |
| Change today | ▼ 5.37% | ▲ 4.07% |
| Market cap | $3.23B | $3.42B |
| Return, 3 months | -1.4% | -22.1% |
| Return, year to date | -12.0% | -23.7% |
| Return, 1 year | +5.4% | -27.0% |
| P/E (TTM) | 116.1 | – |
| P/B | 13.2 | 5.8 |
| P/E percentile vs own 5y | 100th | 85th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +59.3% | – |
| Net profit growth (YoY) | +194.5% | -101.8% |
| Gross margin | 91.1% | – |
| Operating margin | 7.4% | – |
| Net margin | 6.1% | – |
| Return on equity | 15.9% | -96.4% |
| Analyst target vs. price | +55.9% | +241.8% |
| Analyst buy share | 100% | 94% |
| RSI (14) | 39 | 48 |
| 30-day volatility | 92.2% | 70.7% |
| Max drawdown, 1 year | -37.5% | -42.5% |
| Trend read | Leaning bearish | Leaning bearish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- VKTX is the largest of the group by market value.
- ARQT has returned the most over the past year.
- VKTX has been the calmest stock over the last 30 days.